Search

Displaying results 831 - 840 of 1237 in total
  1. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states . It returns UV filters to their ground states without absorbing sunlight . It is used ...

  2. Drug

    Moexipril

    go.drugbank.com/drugs/DB00691
    ApprovedInvestigational

    Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen...

  3. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

  4. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules jo...

  5. Drug

    Lycopene

    go.drugbank.com/drugs/DB11231
    Approved

    However, lycopene is a potent antioxidant molecule that scavenges reactive oxygen species (ROS) singlet oxygen. Tomato lycopene extract is used as a color additive in food products.

  6. Drug

    Phentermine

    go.drugbank.com/drugs/DB00191
    ApprovedIllicitInvestigational

    [A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).

  7. Drug

    Calcitriol

    go.drugbank.com/drugs/DB00136
    ApprovedInvestigationalNutraceutical

    Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate [A26353].

  8. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    available to clear low-density lipoprotein cholesterol (LDL-C), thereby lowering circulating LDL-C levels. … PCSK9 binds low-density lipoprotein receptors (LDLR) on the surface of hepatocytes and promotes their degradation within the liver; by blocking this interaction, enlicitide increases the number of LDLRs

  9. Drug

    Bupropion

    go.drugbank.com/drugs/DB01156
    ApprovedInvestigational

    [L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo

  10. Drug

    ASP-3026

    go.drugbank.com/drugs/DB12729
    Investigational

    has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS